संचार मंत्रालय के राज्य मंत्री (श्री राम निवाल मिर्घा: (क) 31-10-85 को इलाहाबाद में, 8,513 टेलोफल लवेक्शन कार्य कर रहे थे।

- (ख) 31-10-85 को इलाह बाद में नए टेलींकोन कतेन्शनों के लिए 1621 नाम प्रतीक्षा-सूची में थे।
 - (ग) सातवीं योजना के दौरान बर्त-मान प्रतीक्षा-सूची को उत्तरोत्तर निपटाए जाने की संभावना है।

Curtailment of production of essential drugs by M|s Glaxo Laboratories

2209 SHRI PRAVIN KUMAR PRAJA-PATI: Will the Minister of INDUSTRY be pleased to state:

- (a) Whether it is a fact that according to the balance sheets of M|s. Glaxo Laboratories for period ending 30th June, 1984 and 1985 they indicated a continuous process of curtailment of production of essential medicines such as Vaccines and Antibiotics and excess production of ointments, tablets, liquid, and capsules.
- (b) whether it is also a fact that the production of tablets, capsules, ointments and liquids in eight to ten times more than permitted capacity of each whereas production of vaccines and antibiotics indicates srortfall in the same ratio;
 - (c) if so, what are the reasons therefor;
- (d) whether there is any provision under I (D&R) Act or Drug Policy to check unauthorised production and insist obligation of production of essential drugs; and
 - (e) if so, what are the details thereof?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) to (c) The company tailors its production to the market demand; however, the company conforms to the ratio parameters eligible under the 1978 Drug Policy.

(d) and (e) Under the I(D&R) Act. manufacture without a valid industrial approval is an offence. A Company cannot be compelled to produce a particular product, whether essential or not.

Anti-TB Drug

2210. SHRI PRAVIN KUMAR PRAJA
PATI: Will the Minister of INDUSTRY
be pleased to refer to the answer to Unstarred Question 965 given in the Rajva
Sabha on the 25th November, 1985 and
state:

- (a) whether Ethambutol and Rifampicin are Anti-TB and Anti-Leprosy drugs;
- (b) what is the mark up allowed on formulations based on these drugs and what is the mark up allowed on other anti-TB and Leprosy drugs alongwith name of each drug and mark up allowed in each case;
- (c) whether it is a fact that since 1980 formulator, have been making unintended benefits on these medicines if so what is the total amount worked out on these two drug, upto 30th November 1985;
- (d) when did it come to the notice of Government;
- (e) what are the names of companies to whom notices were issued along with date;
- (f) what are the details of amount so far recovered on these medicines;
- (g) whether it is also a fact that Fthambutol is available in open market at Rs. 550|- per Kg; and
- (h) if so., what steps were taken to reduce the prices of Ethambutol formulations?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) Rifamnicin is an Anti-T.B. and Anti-Leorosy drug whereas Ethambutol is an Anti-T.B. drug only.

- (b) Mark-up is allowed in accordance with the provisions of Drugs (Prices Control) Order, 1979 on Anti-T.B. and Anti-Leprosy drug.
- (c) On account of the difference between the price of Rifampicin allowed in the formulations and the actual landed cost of import in spite of six reduction in prices between August 1981 and September 1984 certain excess amount had accrued to the